Lipolysis is a major pathway for the supply of fatty acids to the blood stream. Its importance rests on the fact that fatty acids are a major metabolic fuel for tissues (such as heart and muscle) in the fasted and exercised state; and even in the resting state the oxidation of fatty acids can account for almost all of the basal metabolic rate (Davidson & Passmore 1969) . The major site of activity of lipolysis is in adipose tissue since there is a large store of triglycerides for breakdown to fatty acids and glycerol.
Because of its importance for the delivery of fatty acids to the blood stream, lipolysis is subject to a variety of metabolic controls. These include a fast-acting hormonal component which activates lipolysis over minutes; a slower-acting hormonal component which induces new lipolytic enzymes over a period of days; and various ionic and metabolite controls which modulate the activity of the former. In this paper the fastacting system will be described since the exact molecular details of how hormones, such as adrenaline, can effect a metabolic pathway have been clarified recently.
The first step in the activation of lipolysis by adrenaline is combination of the hormone with a stereo-specific receptor on the plasma membrane of the adipocyte (Fig 1) . This interaction, in a manner not completely understood, activates a membrane-bound enzyme, adenyl cyclase. The latter produces a unique nucleotide, cyclic-AMP, which is an intracellular equivalent of a hormone and has been termed a 'second messenger' (Robison, Butcher & Sutherland 1971) . The novelty of cyclic-AMP is based on the fact that no function has been discovered for it in vertebrates other than as an intracellular signal.
Cyclic-AMP, like an extracellular hormone, combines with an internal receptor in the adipocyte which is closely linked to an enzyme, protein kinase. Protein kinase can be separated into subunits (Robison, Nahas & Triner 1971 ) and when the regulatory subunit combines with cyclic-AMP, the catalytic subunit is activated. The enzyme phosphorylates proteins and in the adipocyte can phosphorylate another enzyme, triglyceride lipase, converting it from an inactive to an active form (Huttenen et al. 1970 ). The latter is responsible for the initial breakdown of triglycerides to fatty acids for delivery to the blood stream. This sequence of three enzymes (cyclase, kinase and lipase) acting in cascade with each other creates several interesting properties (Galton 1971) . Since an enzyme can convert many times its own weight of substrate, linkage of enzymes together functions as a chemical amplifier. A small amount of initial effector (adrenaline) is required to trigger off the first enzyme in the cascade, which activates many times its own weight of the next enzyme, and so on down the series. It allows a small input signal of hormone in blood (10- which provides an amplification factor of about 100 000. A scheme of this activation process is set out in Fig 1 and there is now excellent evidence for the occurrence of each step in the human adipocyte (Burns & Langley 1971 , Tulloch et al. 1972 ). When lipolysis is fully activated it becomes important to have an effective switch-off mechanism. Excessive and continued release of fatty acids into the bloodstream from adipose tissue could cause death due to the toxic effects of high concentrations of fatty acids (resulting in ketoacidosis, denaturation of plasma proteins). Several local tissue mechanisms are available to terminate lipolysis. The enzyme phosphodiesterase actively destroys cyclic-AMP by conversion to 5-AMP. Derivatives of fatty acids, prostaglandins, are released by the adipocyte during lipolysis and these powerfully inhibit adenyl cyclase (Shaw & Ramwell 1968) and prevent further formation of cyclic-AMP. This is a good example of feedback by part of the products of lipolysis inhibiting the first enzyme in the sequence, adenyl cyclase. Finally it is possible that a reset mechanism occurs for the triglyceride lipase by a specific phosphatase which dephosphorylates the activated lipase and so renders it inactive.
It is thus seen how triglyceride lipase in adipose tissue is subject to both positive and negative control in a manner analogous to the control of phosphorylase on the paths of glycogen breakdown. There is also evidence that defects occur on the lipolytic pathway, producing a group of conditions called 'triglyceride storage disease' . Three types have so far been tentatively identified. (1) A defect in hormonal stimulation of the receptor-cyclase segment has been observed in adipose tissue of an infant with peripheral deposits of fat. Hormonal stimulation of the cyclase in this infant was estimated in two ways: by measuring the conversion of 14C-ATP to 14C-cyclic-AMP (Kissebah, Galton, Raju, Kemble & Scopes 1970, unpublished) ; by measuring the direct accumulation of cyclic-AMP in tissue. In each case poor activation of the cyclase was observed in the presence of catecholamines.
(2) A second type of defect has been observed in a large family in which adipose tissue of three obese members appears to be stimulated normally by isoprenaline with regard to cyclic-AMP, but this is associated with a reduced output of glycerol from the tissue (Gilbert et al. 1973) . This points to a defect between cyclic-AMP and triglyceride lipase (possibly at the kinase). (3) Finally in the rare condition of primary familial xanthomatosis (Wolman's disease) there is a defect ofa triglyceride lipase in various internal organs (liver, spleen, intestines) associated with excessive storage of triglyceride in foam cells (Kyriakides et al. 1972 ).
It is not known whether this lipase is hormonesensitive but it may be appropriate to classify this condition with the others as a defect in lipolysis.
Conclusion
The molecular details in the hormonal control of lipolysis in the adipocyte have been described. Several types of metabolic defects occur on the lipolytic pathway in different tissues associated with excess triglyceride storage.
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